» Articles » PMID: 1647690

Mechanisms of Sodium Retention in Heart Failure: Relation to the Renin-angiotensin-aldosterone System

Overview
Journal Am J Physiol
Specialty Physiology
Date 1991 Jun 1
PMID 1647690
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Renal plasma flow (RPF), glomerular filtration rate (GFR), renal proximal tubular delivery of sodium and water evaluated by lithium clearance, and hormonal parameters were measured in 12 patients with congestive heart failure NYHA class II-IV before and after captopril treatment for 4 wk and in 13 healthy control subjects. RPF and GFR were significantly decreased in heart failure, whereas the filtration fraction (FF) was increased. Treatment with captopril increased RPF and decreased FF, whereas GFR was unchanged. Total and fractional urinary excretion of sodium were reduced in the patients compared with the controls, but increased after captopril. Fractional excretion of lithium was normal in heart failure and was increased by captopril. Atrial natriuretic peptide, guanosine 3',5'-cyclic monophosphate, and aldosterone in plasma were significantly elevated in heart failure and were reduced by treatment with captopril. Plasma renin activity was increased in patients, correlated inversely with RPF, and increased further after captopril treatment. It is concluded that the reduced sodium excretion in heart failure was caused by a combination of diminished glomerular filtration and enhanced tubular reabsorption beyond the proximal tubule and that treatment with captopril increased urinary sodium excretion partly due to an attenuated sodium reabsorption in the proximal tubule. The present data in patients with congestive heart failure are consistent with an increased intrarenal angiotensin II generation and an elevated plasma level of aldosterone being involved in the pathogenesis of the glomerular hemodynamic changes and the enhanced distal tubular reabsorption, respectively.

Citing Articles

Correlates of Plasma NT-proBNP/Cyclic GMP Ratio in Heart Failure With Preserved Ejection Fraction: An Analysis of the RELAX Trial.

Chiu L, Agrawal V, Armstrong D, Brittain E, Collins S, Hemnes A J Am Heart Assoc. 2024; 13(7):e031796.

PMID: 38533961 PMC: 11179778. DOI: 10.1161/JAHA.123.031796.


Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.

Butt J, Ibrahim W, Dewan P, Desai A, Kober L, Prescott M Circ Heart Fail. 2023; 16(3):e010111.

PMID: 36943907 PMC: 10022671. DOI: 10.1161/CIRCHEARTFAILURE.122.010111.


Fluid Volume Homeostasis in Heart Failure: A Tale of 2 Circulations.

Miller W J Am Heart Assoc. 2022; 11(18):e026668.

PMID: 36073644 PMC: 9683650. DOI: 10.1161/JAHA.122.026668.


Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.

Miyata K, Lo C, Zhao S, Liao M, Pang Y, Chang S Clin Sci (Lond). 2021; 135(7):943-961.

PMID: 33822013 PMC: 8131957. DOI: 10.1042/CS20210094.


Addition of Tolvaptan Compared With Increased Dose of Furosemide in Heart Failure Patients With Chronic Kidney Disease Under Furosemide Treatment.

Tanaka T, Minatoguchi S, Yamada Y, Kanamori H, Kawasaki M, Nishigaki K Circ Rep. 2021; 1(1):35-41.

PMID: 33693073 PMC: 7925130. DOI: 10.1253/circrep.CR-18-0002.